Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Repligen Corporation ( RGEN ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. Good afternoon, everybody.
Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Repligen Corporation ( RGEN ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Presentation Matthew Stanton Jefferies LLC, Research Division Thanks. My name is Matt Stanton.
Repligen: Rare Growth In The Biopharma Supplies Industry
Repligen stands out as a leading bioprocess supplier, benefiting from secular growth in biologics and industry patent expirations. RGEN's strong balance sheet, recurring organic growth, and strategic acquisitions position it for continued outperformance despite sector volatility. The current depressed valuation and stable financials make RGEN attractive for long-term investors seeking bioprocessing exposure.
Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript
Repligen Corporation ( RGEN ) Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division I'm wrapping up the quarter for a lot of these sessions. As a kickoff, for Repligen, it was a good quarter.
Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript
Repligen Corporation ( RGEN ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Jacob Johnson - Vice President of Investor Relations Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. With that, we're ready to kick things off.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jacob Johnson Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Leonard - UBS Investment Bank, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Steven Etoch - Stephens Inc., Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Brendan Smith - TD Cowen, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Tom DeBourcy - Nephron Research LLC Luke Sergott - Barclays Bank PLC, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Operator Thank you for standing by.
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.43 per share a year ago.
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen Corporation: Still Navigating Through The Covid Cliff
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base through a series of acquisitions and new launches, reducing its reliance on any single customer. RGEN stock is down 60% from its highs in the summer of 2021, and Repligen has a pristine balance sheet.
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Officer Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Justin D.
